PA 452

Modify Date: 2024-01-02 14:25:14

Use of PA 452

PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development[1].

Name	PA452

Description	PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development[1].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR
Target	RXR
In Vitro	PA452 inhibits the Troglitazone (TZ)-induced CK13 expression[2]. PA452 (0.01, 0.1, and 1 μM) inhibits RXR in normal human urothelial (NHU) cells[2].
References	[1]. Iwata M, et al. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol. 2003 Aug;15(8):1017-25. [2]. Varley CL, et al. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol. 2004 May;164(5):1789-98.

Molecular Formula	C₂₆H₃₇N₃O₃
Molecular Weight	439.59

Get all suppliers and price by the below link:

Price: ￥2350/1 mg

Reference only. check more PA 452 price